The leading CRO in the OA field
NBCD is dedicated to clinical drug development, specializing in osteoarthritis. As a science-driven organization, we have several articles published each year in well respected, peer-reviewed journals.
Having worked 30+ years with biomarker development, precision medicine and clinical trials, NBCD has acquired extensive experience within rheumatology and musculoskeletal indications. As the leading CRO in the OA field, we have conducted numerous trials in all clinical phases.
Working closely together with our partners in Sanos Group, we can serve as a one-stop shop for clinical trials in osteoarthritis:
- Sanos Clinic, a network of high-recruiting dedicated research clinics
- Studies&Me, a tech-based recruitment platform with DCT capabilities
- Sanos Supply, a clinical trial supply and packaging facility
- Blueskin, a full-service CRO specialized in dermatology
As a privately owned and highly specialized organization, we can make swift decisions, leverage cross-functional synergies and quickly adapt to accommodate our clients’ current and future needs.
September 06, 2024 |
Sanos Group acquires European CRO specializing in Alzheimer's and CNS |
December 20, 2023 |
Sanos Group acquires biostatistics specialist Omicron |
September 01, 2023 |
Asger Kristensen joins the NBCD Management team |
August 07, 2023 |
New paper published in Osteoarthritis and Cartilage Open |
January 18, 2023 |
OARSI Live Webinar on Phenotyping |
September 17, 2024 |
NLSDays |
September 25, 2024 |
EADV Congress |
September 27, 2024 |
SCRS Global |
October 01, 2024 |
OCT Nordics |
October 29, 2024 |
SCOPE Europe |